Defining Response in Migraine: Which Endpoints Are Important?
Author:
- 1 May 2005
- journal article
- research article
- Published by S. Karger AG in European Neurology
- Vol. 53 (Suppl. 1) , 22-28
Abstract
The primary endpoint traditionally measured in clinical trials of triptans for acute migraine therapy has been 2-hour pain relief, a decrease in pain intensity from moderate/severe to mild/none. Although harder to achieve, endpoints such as 2-hour pain free and the composite measure sustained pain free are now preferred as they better reflect what patients desire from medication, namely rapid onset of action, and complete and lasting relief of pain. A comprehensive meta-analysis has shown that oral triptans differ in their ability to achieve these endpoints, with almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg providing the highest likelihood of success. Although all triptans have simple and consistent pharmacokinetic features, they also have specific differences that may play a part in their differing clinical attributes. Incorporating tolerability to generate a more stringent endpoint, sustained pain free with no adverse events (SNAE), may provide an even better representation of patients’ expectations. Comparison of SNAE rates using data from the meta-analysis of oral triptans indicates that almotriptan 12.5 mg has the best balance of high efficacy and good tolerability.Keywords
This publication has 12 references indexed in Scilit:
- Triptans and CNS Side-EffectsCephalalgia, 2004
- Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraineClinical Therapeutics, 2003
- Migraine Medication Attributes Important for Patient Compliance: Concerns About Side Effects May Delay TreatmentHeadache: The Journal of Head and Face Pain, 2003
- Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 TrialsCephalalgia, 2002
- Determinants of Migraine-Specific Quality of LifeCephalalgia, 2002
- Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trialsThe Lancet, 2001
- Guidelines for Controlled Trials of Drugs in Migraine: Second EditionCephalalgia, 2000
- Acute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy?Headache: The Journal of Head and Face Pain, 1999
- Verbal Scales in the Acute Treatment of MigraineCephalalgia, 1997
- Guidelines for Controlled Trials of Drugs in Migraine. First EditionCephalalgia, 1991